1,125 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Clindamycin Non-Small Cell Lung Carcinoma	Janssen Research & Development, LLC	P2	CC (45)
Eribulin/Farletuzumab Antibody Drug Conjugate Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P2	CC (45)
Eumosone Non-Small Cell Lung Carcinoma	Janssen Research & Development, LLC	P2	CC (45)
Fingolimod Non-Small Cell Lung Carcinoma	Medical University of South Carolina	P2	CC (45)
Fluzoparib Non-Small Cell Lung Carcinoma	Sun Yat-sen University	P2	CC (45)
Frame-001 Personalized Vaccine Non-Small Cell Lung Carcinoma	Frame Pharmaceuticals B.V.	P2	CC (45)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-3101 (89.9%) -(Ighd) -Ighj401 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg101 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-1201 (85.3%)-Igkj201 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa Non-Small Cell Lung Carcinoma	Hummingbird Bioscience	P1/2	CC (45)
gh21 Non-Small Cell Lung Carcinoma	Suzhou Genhouse Bio Co., Ltd.	P1/2	CC (45)
Gls-010 Non-Small Cell Lung Carcinoma	Guangzhou Gloria Biosciences Co., Ltd.	P1/2	CC (45)
ha121-28 Non-Small Cell Lung Carcinoma	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P2	CC (45)
hc010 Non-Small Cell Lung Carcinoma	HC Biopharma Inc.	P2	CC (45)
Human Vascular Endothelial Growth Factor Receptor 1 (Vegfr-1) Fragment 129-228 Comprising The Second Extracellular Domain Of The Vegf Receptor (Vegfr-D2), [N<Sup>196</Sup>>A<Sup>68</Sup>]-Variant, Anti-(Human Vascular Endothelial Growth Factor (Vegf) (1-100 In The Current Sequence) Fused, Via A (G4S)3 Peptide Linker (101-115), To Gamma 1 Heavy Chain (116-563) [Vh (Homo Sapiens Ighv3-2304 -(Ighd) -Ighj401, Cdr-Kabat [5.17.9] (146-150.165-181.214-222)) (116-233) -Homo Sapiens Ighg103 (Ch1 (234-331), Hinge (332-346), Ch2 S<Sup>414</Sup>>A, E<Sup>449</Sup>>A, K<Sup>450</Sup>>A (347-456), Ch3 (457-561), Chs (562-563)) (234-563)], (336-214')-Disulfide With Kappa Light Chain (1'-214') [V-Kappa (Homo Sapiens Igkv1-1201 -Igkj101, Cdrkabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (108'-214')]; Dimer (342-342'', 345-345'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa Non-Small Cell Lung Carcinoma	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P2	CC (45)
Ibi-323 Non-Small Cell Lung Carcinoma	Hunan Province Tumor Hospital	P2	CC (45)
ibi363 Non-Small Cell Lung Carcinoma	Innovent Biologics (Suzhou) Co. Ltd.	P2	CC (45)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cdh6(Cadherin 6, K-Cadherin (Foetal Kidney), Cadherin 6 Type 2)], Humanized Monoclonal Antibody Conjugated To Deruxtecan, Comprising A Linker And A Camptothecin Derivative Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P2	CC (45)
Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Btn1A1 (Butyrophilin Subfamily 1 Member A1)], Humanized Monoclonal Antibody Non-Small Cell Lung Carcinoma	STCube, Inc.	P2	CC (45)
iph5201 Non-Small Cell Lung Carcinoma	Innate Pharma	P2	CC (45)
Jnj-90301900 Non-Small Cell Lung Carcinoma	Johnson & Johnson Enterprise Innovation Inc.	P2	CC (45)
lp-300 Non-Small Cell Lung Carcinoma	Lantern Pharma Inc.	P2	CC (45)
Lparomlimab Non-Small Cell Lung Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CC (45)
L-Til Cells Non-Small Cell Lung Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CC (45)
Milciclib Non-Small Cell Lung Carcinoma	Tiziana Life Sciences LTD	P2	CC (45)
Mirabegron Non-Small Cell Lung Carcinoma	Zhejiang Provincial People's Hospital	P2	CC (45)
Modified Si Jun Zi Tang Non-Small Cell Lung Carcinoma	First Affiliated Hospital of Zhejiang University	P2	CC (45)
Narlumosbart Non-Small Cell Lung Carcinoma	Fudan University	P2	CC (45)
Nogapendekin Alfa Inbakicept Non-Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P3	CC (45)
Odm-212 Non-Small Cell Lung Carcinoma	Orion Corporation, Orion Pharma	P1/2	CC (45)
Ose-279 Non-Small Cell Lung Carcinoma	OSE Immunotherapeutics	P1/2	CC (45)
Part A: Ose-279 Non-Small Cell Lung Carcinoma	OSE Immunotherapeutics	P1/2	CC (45)
Pegargiminase Non-Small Cell Lung Carcinoma	Washington University School of Medicine	P1/2	CC (45)
Rain-32 Non-Small Cell Lung Carcinoma	Rain Oncology Inc	P2	CC (45)
Resiquimod Non-Small Cell Lung Carcinoma	Institut Bergonié	P2	CC (45)
Romiplostim Non-Small Cell Lung Carcinoma	Peking University People's Hospital	P2	CC (45)
Rosiglitazone Non-Small Cell Lung Carcinoma	Dan Zandberg	P2	CC (45)
Ruxoprubart Non-Small Cell Lung Carcinoma	Shanghai Pulmonary Hospital, Shanghai, China	P2	CC (45)
SL-28 Non-Small Cell Lung Carcinoma	Second Life Therapeutics	P1/2	CC (45)
Tacrolimus Non-Small Cell Lung Carcinoma	Janssen Research & Development, LLC	P2	CC (45)
tcc1727 Non-Small Cell Lung Carcinoma	Beijing Tide Pharmaceutical Co., Ltd	P1/2	CC (45)
Timolol Non-Small Cell Lung Carcinoma	Janssen Research & Development, LLC	P2	CC (45)
Trilaciclib Non-Small Cell Lung Carcinoma	The First Affiliated Hospital of Xiamen University	P2	CC (45)
Tuvonralimab Non-Small Cell Lung Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CC (45)
Utomilumab Non-Small Cell Lung Carcinoma	Pfizer	P3	CC (45)
xnw27011 Non-Small Cell Lung Carcinoma	Evopoint Biosciences Inc.	P1/2	CC (45)
yh42946 Non-Small Cell Lung Carcinoma	Yuhan Corporation	P1/2	CC (45)
Zinc D-Gluconate (1:2) Non-Small Cell Lung Carcinoma	Janssen Research & Development, LLC	P2	CC (45)
[14c]-bay2927088 Non-Small Cell Lung Carcinoma	Bayer	P1	CC (44)
Afuresertib Non-Small Cell Lung Carcinoma	Laekna Limited	P1/2	CC (44)
bay2927088 coated Non-Small Cell Lung Carcinoma	Bayer	P1	CC (44)
BO-112 Non-Small Cell Lung Carcinoma	Clinica Universidad de Navarra, Universidad de Navarra	P1/2	CC (44)
Carotuximab Non-Small Cell Lung Carcinoma	Karen Reckamp, MD, MS	P1	CC (44)

Showing 501 to 550 of 1,125 assets

PreviousPage 11 of 23Next